Roche inks $1B+ biobucks deal with Oxford BioTherapeutics for new antibody cancer targets

Roche has forged a multiyear partnership with Oxford BioTherapeutics to find new targets for antibody-based cancer treatments with an upfront payment of $36 million. The partners will work together to identify and verify the antibody ...

Related Posts

Thermo Fisher buys Solventum's purification business fo...

Feb 25, 2025  0

BioNTech vets raise about $90M in Series A for bispecif...

Feb 14, 2025  0

Biogen gets $250M in Royalty Pharma deal for lupus program

Feb 12, 2025  0

Comments

Name

Email

Comment

Post Comment